All news from Urology

Prostate Cancer

Castrate In Prostate Cancer Need Revision

The level of testosterone (T) in the blood of men with riskier; localized prostate cancers who undergo hormone therapy should suppress to a level lower than currently accepted to achieve optimal outcomes; suggests a new retrospective study. Androgen deprivation therapy (ADT) is a standard treatment for some men with intermediate- and high-risk prostate cancer. That not yet spread…

Prostate Cancer

Finasteride Increasing The Risk Of Prostate Cancer

Long-standing concerns about the consequences of finasteride are increasing the risk of high-grade prostate cancer “have not been borne out;” report investigators from the landmark Prostate Cancer Prevention Trial (PCPT). This trial previously indicated that finasteride; a 5-alpha-reductase inhibitor commonly used for benign prostatic hyperplasia and male pattern baldness; is an active chemopreventive agent for prostate cancer. High-Grade Prostate Cancer However,…

Prostate cancer

Safe, Effective Prevention For Prostate Cancer

Finasteride, a generic hormone-blocking drug, was found to reduce the risk of prostate cancer by 25 % in the landmark Prostate Cancer Prevention Trial (PCPT). Therefore Long- term data, published today in the New England Journal of Medicine, show that reduction in prostate cancer risk has continued and fewer than 100 men on the trial died…

Detection Of Common Sexually Transmitted Infections

Hologic, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted clearance for its Aptima Mycoplasma genitalium assay, the first and only FDA-cleared test to detect this under-recognized but increasingly common sexually transmitted infection (STI). This newest Aptima assay joins a growing suite of market-leading tests offered by Hologic to help combat the rise of STIs in the U.S.

Urinary Tract Infection May Depend On The Bacterial Strain

Genetically diverse bacterial strains that cause urinary tract infections differ in their ability to trigger protective immune responses in mice, potentially explaining why these infections frequently recur in many patients, according to a study published December 13 in the open-access journal PLOS Pathogens by Thomas Hannan and Scott Hultgren of Washington University School of Medicine, and colleagues.

FDA Grants: Designation For Wearable PD Device

The FDA has granted breakthrough device designation to its wearable PD system that incorporates AWAK's sorbent technology. According to a company press release, the FDA's breakthrough designation is granted to expedite the development and review of certain devices that demonstrate potential to provide a more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases.

Gene May Contribute To Drug Resistance In Prostate Cancer

Researchers have discovered how a gene involved in regulating hormone receptors may contribute to drug resistance in some prostate cancer patients. Their findings, published in eLife, suggest that disrupting specific activity of the GREB1 gene could be explored for developing more effective therapies in future.